New Features and Design Further Strengthen MSActiveSource.com
CAMBRIDGE, Mass., July 25 /PRNewswire-FirstCall/--
Biogen, Inc. (Nasdaq: BGEN) announced today the launch a newly enhanced
MSActiveSource.com (http://www.msactivesource.com), the premier destination on
the Internet for information on multiple sclerosis (MS). The site serves
nearly half a million Americans whose lives are touched by the disease.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
"Biogen is committed to keeping MSActiveSource.com up-to-date with the
most current information on MS, its treatment, and research results," said Rob
Perez, Biogen's Vice President, CNS Business Unit. "MSActiveSource.com is now
an even more valuable resource for those seeking a better understanding of
MS."
Based on input from people with MS and their caregivers,
MSActiveSource.com has been enhanced to meet evolving user needs. The site
offers simple, customizable content from the most comprehensive cache of
information about the disease available on the Internet.
The features on the site have been reorganized and enhanced even beyond
their previous utility. The one-of-a-kind MS Learning System(TM) provides
current, rich, scientific information on the disease. The "Living with MS"
section contains valuable tips and articles written both by healthcare
professionals and people with MS for their peers. MSActiveSource.com is
updated daily with news and information on MS research, alternative therapies,
upcoming events, and offers direct links to other MS sites.
Members of MSActiveSource.com have unlimited access to a growing
interactive community, including message boards and a mentor program that
allows members to communicate one-on-one with another person with MS. Members
can organize these and other helpful tools easily on their personalized
homepages. Membership takes just a few minutes to complete, and opens the
door for members to benefit further from Biogen's commitment to MS treatment.
About AVONEX(R) (Interferon-beta 1a)
AVONEX is the leading treatment for relapsing forms of multiple sclerosis
worldwide, with more than 121,000 patients on therapy. It was launched in the
U.S. in 1996 and later in Europe for the treatment of relapsing forms of MS to
slow the progression of disability and reduce relapses. AVONEX is marketed
internationally in more than 65 countries.
The most common side effects associated with AVONEX treatment are flu-like
symptoms, muscle ache, fever, and chills. Other common side effects seen, but
not statistically different between AVONEX and control groups, were headache,
pain and asthenia (weakness). These side effects usually go away within a day
after the injection and occur less often as the treatment continues.
AVONEX should be used with caution in people with depression and people
with seizure disorders. AVONEX should not be used by pregnant women. People
with cardiac disease should be closely monitored. Routine periodic blood
chemistry and hematology tests are recommended during treatment with AVONEX.
Please see complete prescribing information available at http://www.Avonex.com.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biopharmaceutical company principally engaged in discovering and developing
drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company's revenues are generated from U.S. and worldwide
sales of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of
multiple sclerosis, and from the worldwide sales by licensees of a number of
products, including alpha interferon and hepatitis B vaccines and diagnostic
products. Biogen's research and development activities are focused on novel
products to treat inflammatory and autoimmune diseases, neurological diseases,
cancer, fibrosis and congestive heart failure. The Company maintains active
clinical research programs in protein therapeutics, small molecules, genomics
and gene therapy. For copies of press releases and additional information
about the Company, please consult Biogen's Homepage on the World Wide Web at
http://www.biogen.com.
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
http://www.msactivesource.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
CONTACT:
Tim Hunt, Director, Public Affairs,
+1-617-679-4996, or Christina Dillon, Manager, Investor
Relations, +1-617-679-2521, both of Biogen, Inc.
|
